Max-Bio takes 11.89% of BSE-listed Raconteur Global via share issue
What's the deal? Max-Bio Biosciences has acquired an 11.89% stake in Bombay Stock ExchangeDealroom has a profile for this one. Try Dealroom →-listed Raconteur Global ResourcesDealroom has a profile for this one. Try Dealroom → through a preferential allotment of shares. The transaction, completed on September 8, 2026, involved 2,142,857 equity shares carrying voting rights.
The mechanics: Because the stake came via new shares rather than a market purchase, Raconteur's total equity share capital rose to 180,278,420 shares after the deal. Max-Bio is not part of Raconteur's promoter or promoter group.
What we don't know: The valuation per share and total deal value were not disclosed. The filing confirms there were no warrants, convertible securities, or other instruments entitling Max-Bio to further voting shares.
The paper trail: Max-Bio filed the disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The document was signed by Surinder Kalra, director of Max-Bio BiosciencesDealroom has a profile for this one. Try Dealroom →, on September 21, 2026.
The signal: A near-12% position acquired outside the promoter group makes Max-Bio a substantial shareholder, a stake large enough to matter in future governance votes. With terms undisclosed, the open question is what a bioscience firm sees in a resources company — and at what price.
Image credit: Ken Lund
